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Abundant expression of the IL-23 subunit p19, but low levels of
bioactive IL-23 in the rheumatoid synovium
Abstract
OBJECTIVE: IL-23, composed of a p19 and a p40 subunit, is suggested to play key roles in rheumatoid
arthritis (RA), dependent on the promotion and proliferation of IL-17-producing Th17 T-cells. However,
previous studies on IL-23 expression in human tissues were based on p19 only. We aimed to study the
expression and regulation of both IL-23 subunits, p19 and p40, in RA compared to osteoarthritis (OA)
patients. METHODS: The expression of p19 and p40 in synovial tissues was analyzed by in-situ
hybridization and immunohistochemistry. IL-23 in RA and OA synovial fluids and sera was determined
by ELISA. TLR-dependent induction of p19, p40 and bioactive IL-23 was determined in RASF,
monocytes and MDDC by RT-PCR, Real-time PCR, Western-blot and functional-assays. RESULTS:
The p19 subunit was abundantly expressed in RA but not in OA synovial tissues. p19 was most
prominently expressed by RASF in the synovial lining layer and at the site of invasion, but no
heterodimeric IL-23 was detected at these sites. Correspondingly, soluble IL-23 was not detectable or
found at very low levels in synovial fluids and sera of patients with RA. By in-vitro experiments, we
confirmed that TLR-activated RASF expressed p19 but not p40, in contrast to monocytes, which
produced IL-23 following TLR stimulation. CONCLUSION: The TLR-dependent induction of p19 but
not p40 in RASF and the abundant expression of p19 along with the low or undetectable levels of IL-23
in RA patients, gives strong evidence that p19 does not necessarily indicate the presence of IL-23 as it
has been proposed so far.
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Abstract: 
Objective: 
IL-23, composed of a p19 and a p40 subunit, is suggested to play key roles in rheumatoid 
arthritis (RA), dependent on the promotion and proliferation of IL-17-producing Th17 T-cells. 
However, previous studies on IL-23 expression in human tissues were based on p19 only. We 
aimed to study the expression and regulation of both IL-23 subunits, p19 and p40, in RA 
compared to osteoarthritis (OA) patients.  
Methods: 
The expression of p19 and p40 in synovial tissues was analyzed by in-situ hybridization and 
immunohistochemistry. IL-23 in RA and OA synovial fluids and sera was determined by 
ELISA. TLR-dependent induction of p19, p40 and bioactive IL-23 was determined in RASF, 
monocytes and MDDC by RT-PCR, Real-time PCR, Western-blot and functional-assays. 
Results:  
The p19 subunit was abundantly expressed in RA but not in OA synovial tissues. p19 was 
most prominently expressed by RASF in the synovial lining layer and at the site of invasion, 
but no heterodimeric IL-23 was detected at these sites. Correspondingly, soluble IL-23 was 
not detectable or found at very low levels in synovial fluids and sera of patients with RA. By 
in-vitro experiments, we confirmed that TLR-activated RASF expressed p19 but not p40, in 
contrast to monocytes, which produced IL-23 following TLR stimulation.  
Conclusion: 
The TLR-dependent induction of p19 but not p40 in RASF and the abundant expression of 
p19 along with the low or undetectable levels of IL-23 in RA patients, gives strong evidence 
that p19 does not necessarily indicate the presence of IL-23 as it has been proposed so far.  
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Introduction: 
 
Interleukin-23 (IL-23) is a heterodimeric cytokine composed of a p19 and a p40 subunit 
which is shared with IL-12. The p19 subunit has been identified by computational screening 
of the IL-6 helical cytokine family. Purified p19 has no biological activity in vitro, whereas 
p19 combined with the p40 subunit forms the heterodimeric and biologically active cytokine 
IL-23 [1]. The major source of IL-23 are macrophages and dendritic cells. Toll-like receptor 
agonists and interactions with T cells (CD40/CD40L interaction) were shown to trigger the 
induction of  bioactive IL-23 [2-4]. IL-23 is related to IL-12 but has functionally distinct 
properties. IL-12 is composed of the p40  and the p35 subunit, which has an overall sequence 
identity of approximately 40% to the p19 subunit. In contrast to IL-12, IL-23 does not 
promote the development of IFN-gamma producing Th1 CD4+ cells, but is one of the 
essential factors required for the maintenance and survival of  a recently described  IL-17 
producing CD4+ T-cell subset, named Th17 [5]. Expression of IL-17 has been detected in 
sera and tissues of patients with various autoimmune diseases, including rheumatoid arthritis 
(RA), multiple sclerosis and systemic lupus erythematosus [6-8].  
RA is a chronic inflammatory disease that is characterized by the destruction of articular 
cartilage and bone. RA synovial fibroblasts (RASF) play a major role in the destruction of the 
joint by secreting matrix degrading enzymes. Moreover, a hallmark of RA is synovial 
hyperplasia that is caused by the proliferation of resident RASF and by the accumulation of 
inflammatory immune cells including B cells, T cells and macrophages. IL-23 is suggested to 
be essential in autoimmune inflammation in joints as p19 and p40 deficient mice exhibit 
reduced severity of collagen induced arthritis [9]. In humans, levels of p19 as well as p40 
were shown to be elevated in synovial fluids and sera of patients with RA compared to 
osteoarthritis (OA) [10, 11]. These data suggested high expression of IL-23 in joints of RA 
patients even though the presence of heterodimeric IL-23 has not been ascertained so far. 
There is mounting evidence for an activation of toll-like receptor (TLR) signalling pathways 
in RA. We and others have shown in previous reports elevated TLR2,3 and 4 levels in 
synovial tissues of  patients with RA compared to OA. Furthermore, RASF stimulated with 
TLR2, 3 and 4 ligands produce high amounts of cytokines, chemokines and matrix 
metalloproteinases that are characteristically found in joints of RA patients. Regarding the 
induction of IL-23 in RASF, it has been demonstrated that the p19 subunit is upregulated by 
IL-1β or IL-17 [10, 12]. However, whether RASF have the potential to produce heterodimeric 
IL-23 after TLR activation remains to be determined.  
The purpose of our study was to analyze the presence of heterodimeric IL-23 in RA and OA 
synovial tissues by immunohistochemistry and to determine levels of soluble IL-23 in RA and 
OA synovial fluids and sera by enzyme-linked immunoabsorbent assay. Furthermore, we 
analyzed the induction of both IL-23 subunits, p19 and p40, in RASF, human primary blood 
monocytes and monocytes derived dendritic cells (MDDCs) after stimulation with TLR2, 3 
and 4 ligands.  
 
 
.
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Materials and Methods: 
Patients and tissue preparation 
Synovial tissue specimens were obtained during synovectomy or joint replacement surgery 
from patients with RA and OA, after informed consent had been obtained (Department of 
Orthopedic Surgery, Schulthess Clinic, Zurich, Switzerland). RASF and OASF were isolated 
from synovial tissues, digested by collagenase, and used after passages 4 to 8 as described 
[13]. To obtain tissue sections, synovial specimens were fixed in paraformaldehyd and 
embedded in paraffin. Sera and synovial fluids from patients with RA and OA were collected, 
centrifuged and stored at -80° until analysis. Before analysis, synovial fluid samples were pre-
treated for 1 hour at 37°C with 1 mg/ml of hyaluronidase (Fluka, Buchs, Switzerland). All RA 
patients fulfilled the American College of Rheumatology criteria for the classification of RA 
[14]. 
 
In situ hybridization 
IL-23 sense and IL-23 antisense probes for in situ hybridization (ISH) were prepared 
according to methods previously described. The primer sequences were as follows: upper 
primer 5'-CTA TCA GGG AGC AGA GAA G-3'; and lower primer, 5'- ACT AGT GGG 
ACA CAT GGA T-'3. [15]. ISH was performed as described by Kriegsmann et al.[16]. 
 
Immunohistochemistry 
After the detection of IL-23 mRNA in RA synovial tissues by ISH, subsets of synovial cells 
expressing p19 were analyzed by double labeling the p19 mRNA stained sections with 
monoclonal mouse anti-human CD68 or anti-human vimentin antibodies (2µg/ml, Dako, 
Glostrup, DK), respectively. Bound mouse primary antibodies were detected using 
horseradish peroxidase (HRP) conjugated goat anti-mouse IgG antibodies (Jackson 
ImmunoResearch Europe, Soham, UK). HRP labelled cells were visualized using AEC (3-
Amino-9-Ethylcarbazol) substrate-chromogen (Dako). 
In order to analyze IL-23 protein expression, consecutive synovial tissue sections 
derived from patients with RA or OA were stained for p19 or/and p40. The catalyzed signal 
amplification (CSA) system for mouse primary antibodies was used according to the 
manufacturers instruction (Dako). Briefly,  tissue sections were deparaffinized and pretreated 
with target retrieval solution. Endogenous avidin-binding activity was blocked with the 
avidin/biotin blocking system and endogenous peroxidase was blocked with 1.5% H2O2. 
After blocking unspecific IgG binding with protein block solution, sections were incubated 
for 15 min with mouse anti-human p19 antibodies (10ug/ml, BioLegend, San Diego, CA) or 
mouse anti-human p40 antibodies (10ug/ml, AbD Serotec, Germany). Sections were then 
incubated with biotinylated link antibodies, Streptavidin-biotin complex solution, 
amplification reagent and streptavidin-peroxidase. HRP-labelled cells were visualized using 
DAB (3,3’-diaminobenzidine tetrahydrochloride) or Histo-green substrate-chromogen. In 
control experiments, isotype matched mouse IgG were used instead of the primary antibodies. 
Tissues were counterstained with hematoxylin. 
 
Stimulation assays with rheumatoid arthritis synovial fibroblasts  
RASF were cultured in DMEM (Gibco, Basel, Switzerland) supplemented with 10% FCS and 
stimulated with the following agents: polyinosinic-polycytidylic acid (poly(I-C), 20 µg/ml; 
Invivogen, San Diego, CA), lipopolysaccharide from E. coli (LPS, 100 ng/ml; List 
Biologicals, Campbell, CA), palmitoyl-3-cysteine-serine-lysine-4 (bLP, 300 ng/ml, 
Invivogen). 
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Isolation and stimulation of monocytes and generation of monocyte derived dendritic 
cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from Buffy coats of healthy 
volunteers with Ficoll-Paque™ PLUS (Amersham Biosciences, Uppsala, Sweden) gradient 
centrifugation. Peripheral blood monocytes were positively separated from PBMCs with 
CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
manufacturers protocol. The purity of the CD14+ cell fraction, as assessed by flow cytometry, 
was consistently over 90%. CD14+ cells were transferred in 12-well plates, cultured in RPMI-
1640 supplemented with 5% FCS and stimulated with bLP (300 ng/ml), poly(I-C) (10ug/ml) 
or LPS (100ng/ml) for 24h.  
For the generation of monocyte derived dendritic cells (MDDCs), CD14+ cells were 
cultured for 6 days in RPMI-1640, supplemented with 10% FCS, interleukin 4 (IL-4, 500 
U/ml; R&D Systems, Abington, UK ) and granulocyte monocyte-colony stimulating factor 
(GM-CSF, 800 U/ml; R&D Systems).  Fresh complete culture medium was added after 3 
days. At day 6 the immature MDDCs (iMDDCs) were harvested. To generate mature 
MDDCs, iMDDCs were transferred to new 12 well culture plates in fresh complete culture 
medium and stimulated for 24h with bLP (300 ng/ml), poly(I-C) (10ug/ml) or LPS 
(100ng/ml). Expression of cell surface markers (CD14, CD86, HLA-DR and CD83) on 
iMDDCs and mMDDCs was measured by fluorescence activated sell sorter (FACS) analysis 
in order to confirm corresponding phenotypes. 
 
Isolation and stimulation of CD8+ T-cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from Buffy coats of healthy 
volunteers with Ficoll-Paque™ PLUS (Amersham Biosciences, Uppsala, Sweden) gradient 
centrifugation. T-cells were positively separated from PBMCs with CD8 microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturers protocol. 
CD8+ cells were transferred in 96-well plates, which were precoated with anti-CD3 
antibodies (BD Pharmingen, Erembodegem, Belgium) for 24h at 5µg/ml. CD8+ T-cells were 
cultured in RPMI-1640 supplemented with 5% FCS in presence of anti-CD28 antibodies (BD 
Pharmingen) at 5µg/ml. CD8+ cells were stimulated either with recombinant human IL-23 
(R&D Systems) at 1ng/ml, 10ng/ml, 100ng/ml or with supernatants of RASF and monocytes 
stimulated with TLR ligands bLP, poly(I-C) and LPS as described above.  
 
 
Real-time PCR 
Total RNA from cultured RASF, monocytes and MDDC was isolated with the RNeasy 
MiniPrep Kit including treatment with RNase-free DNase (Qiagen, Basel, Switzerland) and 
reverse transcribed using random hexamers and multiscribe reverse transcriptase (both 
Applied Biosystems, Rotkreuz, Switzerland). Non reverse transcribed samples were used as 
negative controls. Quantification of p19 and p40 mRNA was performed by Taqman Real-time 
PCR using the ABI Prism 7700 Sequence Detection system (Applied Biosystems). The 
following validated TaqMan® gene expression assays (Applied Biosystems) were used: 
IL23A (p19) (Hs00372324_m1) and IL12B (p40) (Hs00233688_m1). The endogenous 
control 18S cDNA was used for correcting the results with the comparative threshold cycle 
(Ct) method for relative quantification as described by the manufacturer. 
 
Conventional RT-PCR 
Total RNA was isolated as described above for Real-time PCR and reverse transcribed using 
oligo(dT) and moloney murine leukemia virus (MuLV) reverse transcriptase (both Invitrogen, 
Switzerland). Conventional PCR was performed on a GenAmp PCR System 9700 (Applied 
Biosystems, Rotkreuz, Switzerland) with the following primer pairs and protocols. p19: 
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forward primer 5'- CTA TCA GGG AGC AGA GAA G -3', reverse primer 5'- ACT AGT 
GGG ACA CAT GGA T -3'; p40 forward primer 5'-ATG TCG TAG AAT TGG ATT GG -3', 
reverse primer 5'-AGG TGA AAC GTC CAG AAT AA -3'; βmicroglobulin forward primer 
5'-AAG ATT CAG GTT TAC TCA CGT C-3', reverse primer 5'-TGA TGC TGC TTA CAT 
GTC TCG-3'.  5min 94°C; 30 cycles 30s at 94°C, 30s at Tm (Tm 54°C for p19, Tm 54°C for 
p40, Tm 56°C for β-microglobulin), 30s at 72°C; and a final elongation of 5min with 72°C. 
Reaction products were separated on a 1% agarose gel and signals were visualized using 
ethidium bromide. As a negative control, PCR was carried out in the absence of cDNA for 
each set of primers. 
 
Enzyme linked immunoabsorbant assay (ELISA) and enzyme immunoassay (EIA) 
IL-23 heterodimer was detected using a human IL-23 ELISA Kit (eBioscience, San Diego, 
CA) according to the manufacturers instructions. IL-17 was measured with a human IL-17 
DuoSet kit (R&D Systems) following the manufacturers instructions. Absorption was 
measured at 450 nm and data were analyzed using Revelation v4.22 software (Dynex 
Technologies, Denkendorf, Germany). 
 
Western blot 
RASF were stimulated for 24h with TLR ligands before cells were lysed in Laemmli-Buffer. 
Proteins were separated on 10% SDS-polyacrylamide gel and blotted on Protran nitrocellulose 
transfer membrane (Schleicher & Schüll, Dassel, Germany). Membranes were probed with 
anti-p19 antibodies (0.5 µg/ml, BioLegend) and detected with HRP-conjugated second 
antibodies using the ECL Western blotting detection system (Amersham Pharmacia Biotech). 
Blots were stripped and reprobed with monoclonal mouse anti human α-Tubulin (Sigma) 
antibodies to confirm similar loading of the gels. 
 on 4 August 2008 ard.bmj.comDownloaded from 
 7
 
Results: 
 
Abundant IL-23 p19 mRNA expression in RA synovial tissues 
To investigate whether IL-23 might play a role in the pathogenesis of RA we analyzed the 
presence and distribution of the IL-23 subunit p19 in the rheumatoid joint. Expression of p19 
was assessed by in situ hybridization with an anti-p19 mRNA probe using paraffin embedded 
RA synovial tissue sections (n=5). We observed p19 mRNA positive cells throughout the 
synovium.  The most marked expression of p19 mRNA was found in the synovial lining layer 
as well as at sites of invasion into cartilage. (Figure 1A, C). Control sections hybridized with 
sense- p19 mRNA probe showed no signal (Figure 1B, D). Furthermore, double staining with 
cell type specific markers revealed that p19 positive cells expressed the fibroblast marker 
vimentin or the macrophage marker CD68 (Figure 1E, F), documenting strong p19 mRNA 
expression by RA synoviocytes.  
 
Differential p19 and p40 protein expression in RA and OA synovial tissues 
IL-23 is a heterodimer consisting of the p19 and the p40 subunit, the latter being shared with 
IL-12. In order to examine whether p19 protein expression co-localizes with p40 protein 
expression we performed immunohistochemical analysis for p19 and p40 on consecutive RA 
synovial tissue sections (n=9). In RA synovial tissues p19 protein was abundantly expressed 
and the distribution corresponded to the presence of p19 mRNA as detected by in situ 
hybridisation (Figure 2A). In contrast to the broad expression of the p19 subunit, p40 protein 
expression was found to be restricted to few cell clusters scattered in the synovium (Figure 
2B). These results revealed, that most p19 expressing synoviocytes do not co-express the p40 
subunit. Control sections incubated with matched isotype antibodies showed no signal (Figure 
2C,F). In addition we analyzed the expression of p19 and p40 in synovial tissues derived from 
patients with osteoarthritis (OA). Both subunits, p19 and p40, were not, or very weakly 
expressed in OA synovial tissues (n=8) (Figure 2D, E). Thus, the subunits p19 and p40 might 
be implicated in the pathogenesis of RA but not OA. 
 
To address the question whether heterodimeric IL-23 is present in joints of RA patients we 
performed immunohistochemical double stainings for p19 and p40 on RA synovial tissue 
sections (n=6). The majority of synoviocytes in the synovial lining layer as well as in the 
sublining were single positive for p19 (Figure 2G,H). In addition we also detected p40 single 
positive cells (Figure 2H). However, within some p40 positive cell clusters we found p19/p40 
double positive cells (Figure 2H insert). Control sections incubated with matched isotype 
antibodies showed no signal (Figure 2J). These results demonstrate that   the majority of cells 
did not express p40 and therefore no heterodimeric IL-23. 
Activated dendritic cells are known to produce heterodimeric IL-23 (1). Therefore, to analyze 
whether p19/p40 double positive cells in the synovium might be dendritic cells we performed 
double stainings with the dendritic cell marker CD83 and p40, as p40 seemed to be the 
limiting factor for the potential production of IL-23. p40 positive cells coexpressed the 
dendritic cell marker CD83 (Figure 3A), suggesting that dendritic cells in the synovium have 
the capability to coexpress both subunits of IL-23   
 
Levels of soluble IL-23 in RA and OA synovial fluids and sera 
The concentration of the shared IL-12/IL-23 subunit p40 was reported to be elevated in 
synovial fluids of RA patients compared to controls [11, 17] and high levels of soluble p19 
protein in RA synovial fluid and serum samples were demonstrated recently by Kim et al. 
[10]. By immunohistochemical analysis we detected only a small number of p19/p40 double 
positive cells in RA synovial tissues. To assess the concentrations of soluble IL-23 in synovial 
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fluids and sera from patients with RA and OA we performed ELISA specific for the IL-23 
heterodimer (Figure 4). In only 6 out of 37 synovial fluids derived from patients with RA and 
in only 2 out of 21 synovial fluids of patients with OA we were able to detect concentrations 
of IL-23 above the detection limit (range: 16-29pg/ml IL-23). Similarly, we also detected only 
small amounts of IL-23 in 10 out of 37 RA sera and in 9 out of 29 OA sera (range: 16-
114pg/ml IL-23). No statistically significant difference of IL-23 levels between RA and OA 
synovial fluids and sera were observed. 
 
Differential regulation of p19 and p40 expression by TLR ligands  
As RA synoviocytes express elevated levels of TLR2, 3 and 4, we assessed TLR dependent 
regulation of the IL-23 subunits p19 and p40 in different cell types. RASF, monocytes or 
monocyte derived dendritic cells (MDDCs) were stimulated with the TLR2 ligand bLP, the 
TLR3 ligand poly(I-C) and the TLR4 ligand LPS. 24h following stimulation we determined 
the presence and the induction of the two IL-23 subunits by conventional RT-PCR as well as 
by quantitative real-time PCR. RASF did not express p19 mRNA constitutively (Figure 5A). 
However after stimulation with TLR2, 3, and 4 ligands p19 mRNA was found to be induced 
in RASF (Figure 5A, B). The most prominent induction was seen after TLR3 activation with 
poly(I-C) (24.5 ±2.1 fold upregulation relative to unstimulated cultures, n=5). Conversely, 
p40 mRNA was neither expressed in unstimulated nor in TLR ligand stimulated RASF. In 
two RASF cultures derived from individual patients the induction of p19 protein by TLR 
ligands was confirmed on protein levels by Western blot analysis (Figure 5C). As a positive 
control we used monocytes and MDDCs as it has been demonstrated that these cells have the 
capability to produce both subunits of IL-23.  In primary monocytes both IL-23 subunits were 
inducible to similar levels by bLP as well as by LPS (Figure5 A,B). However no constitutive 
mRNA expression was detected for p19 nor p40 (Figure 5A). Because monocytes do not 
express TLR3, neither p19 nor p40 mRNA was detected after stimulation with poly(I-C). 
MDDCs constitutively expressed the p40 subunit (Figure 5A). In addition p40 mRNA was 
strongly upregulated following stimulation with bLP and LPS as well as with poly(I-C) 
(Figure 5A,B). The p19 subunit was not expressed in unstimulated MDDCs but was induced 
after stimulation with the TLR2, 3 and 4 ligands. Thus, TLR activated monocytes and 
MDDCs have the potential  to induce both subunits necessary for the production of bioactive 
IL-23, whereas TLR activated RASF express the p19 subunit only.  
 
Activated Monocytes but not RASF secrete bioactive IL-23 
It has been demonstrated that stimulation of CD8+ T-cells with rhIL-23 results in the 
production of IL-17 [18]. To assess whether monocytes or RASF  secrete biologically active 
IL-23,  we stimulated polyclonally activated CD8+ T-cells with supernatants of TLR ligand 
stimulated monocytes and RASF and measured IL-17 production.  Stimulation of activated 
CD8+ T-cells with rhIL-23 served as a positive control. IL-17 production by activated CD8+ 
T-cells was dose dependently upregulated by rhIL-23. Similarly, the addition of supernatants 
of TLR2 activated monocytes to CD8+ T-cell cultures resulted in an 1.4±0.2 fold upregulation 
of IL-17 and supernatants of TLR4 activated monocytes in a 3.6±0.2 fold upregulation of IL-
17 production by activated CD8+ T-cells. In contrast, treatment of CD8+ T-cells with 
supernatants of TLR2, 3 or 4 activated RASF had no effect on the IL-17 production. These 
results confirmed that RASF stimulated with TLR ligands, although expressing the p19 
subunit, do not produce bioactive IL-23 in contrast to TLR activated  monocytes.  
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Discussion: 
In the current study we demonstrate that p19 is expressed and induced independently of p40 
in RASF in contrast to MDDCs and monocytes. In addition we show that heterodimeric IL-23 
is present at unexpectedly low levels in joints of RA patients. 
Recent reports have indicated the involvement of IL-23 in several autoimmune 
diseases including colitis, psoriasis and arthritis. Treatment with anti-p19 antibodies in mice 
inhibited central nervous system autoimmune inflammation, prevented active colitis and 
exacerbated lyme arthritis [19-21]. In the collagen induced arthritis mouse model, p19 and 
p40 are essential for the development of joint inflammation [9]. However, studies regarding 
the role of IL-23 in RA have not been published so far. We show that IL-23 is barely 
detectable in joints of RA patients. Only a small number of p19/p40 double positive cells 
were detected in RA synovial tissues. In accordance with this finding we could detect 
heterodimeric IL-23 in only 5 out of 28 patients. This result was unexpected as high p40 and 
high p19 levels were described in earlier reports [7, 10]. Interestingly, p40 seemed to be the 
limiting factor for the production of IL-23 as most synoviocytes were single positive for p19. 
In addition we found p40 positive/p19 negative cells, presumably secreting the related 
cytokine IL-12, which is composed of the p40 and p35 subunits. In accordance IL-12 positive 
cells have been described in the sublining layer of the RA synovium [22].  
IL-23 was shown to be expressed by activated dendritic cells, monocytes, 
keratinocytes and microglia [18, 25-27]. The activity of inflammatory cells can be influenced 
by the activation of TLRs that interact with microbial or endogenous ligands. In earlier reports 
we have demonstrated that TLR2, 3 and 4 expression is elevated in RA synovial tissues [28-
31]. Endogenous TLR ligands, such as heat shock proteins and necrotic cells, are present in 
the chronically inflamed joints and may lead to a sustained activation of TLR signalling 
pathways in RA. In the current study we show differential expression and induction of the IL-
23 subunits by TLR2, 3 or 4 ligands in RASF, monocytes and MDDC.  We found  that TLR 
activation induced p19 but not p40 protein expression in RASF whereas in MDDCs and 
monocytes both IL-23 subunits were upregulated. Stimulation of pre-activated CD8+ T-cells 
with rhIL-23 as well as with supernatants of TLR activated monocytes but not TLR activated 
RASF led to an increase in the production of IL-17. Therefore, we assume that activated 
dendritic cells and monocytes or macrophages are the main producers of heterodimeric IL-23 
in the RA synovium whereas RASF express p19 independently of p40. This is the first study 
showing differential expression of IL-23 subunits in the synovium. Consequently p19 
expression does not necessarily correlate with the presence of bioactive IL-23 as has been 
assumed in previous reports [10, 32]. 
Ubiquitous transgenic expression of p19 in mice results in a phenotype of systemic 
inflammation, impaired growth and premature death [33]. Additionally, high levels of TNF-
α 
and IL-1β were detected in the circulation of p19 transgenic mice. It has been suggested that 
the development of multiorgan inflammation in p19 transgenic mice is dependent on the 
dimerization of p19 with p40 and therefore dependent on the heterodimer IL-23. However, the 
p40 subunit was not detectable in serum of p19 transgenic mice. These findings together with 
our data showing a large number of p19 positive / p40 negative synoviocytes in the RA 
synovial lining layer and at sites of invasion, gives further evidence that p19 may be 
implicated in the RA pathogenesis independently of its dimerization with p40. The p19 
protein shares homology with members of the IL-6/IL-12 family which includes IL-6, 
oncostatin M, G-CSF and p35. It has been speculated that additional heterodimeric complexes 
might exist in the IL-12 family which comprises IL-12, IL-23 as well as IL-27. For example 
combinations of Epstein-Barr virus-induced gene 3 (EBI3) and p35 as well as EBI3 and p19 
have been described [34]. Whether p19 might have additional binding partners other than p40 
in vivo needs further investigation. 
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In conclusion we report abundant expression of p19 but not heterodimeric IL-23 by 
RASF at sites of invasion and in vitro upon stimulation by TLR ligands. The differential 
expression of p19 and p40 suggests that p19 does not necessarily indicate the presence of 
active IL-23 and gives evidence for a p40 independent involvement of p19 in the pathogenesis 
of RA 
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Figure Legends: 
 
Figure 1: In RA synovial tissues p19 mRNA is expressed by synoviocytes 
Representative sections of RA synovial tissues (n=5) hybridized in situ with specific antisense 
RNA probes for p19 mRNA. p19 mRNA was detected most marked at sites of invasion into 
cartilage (A) and in the synovial lining layer (C). Cells expressing p19 mRNA appear in dark 
blue. As negative control, tissue sections were hybridized with the corresponding p19 sense 
probes ( B, D).  
Sections stained for p19 mRNA were further labeled by immunohistochemical analysis with 
anti-CD68 antibodies as macrophage markers (E) or anti-vimentin antibodies as fibroblast 
markers (F). CD68 or vimentin positive cells appear in red colour.  
 
Figure 2: In RA synovial tissues p19 and p40 are differentially expressed 
Representative sections of RA synovial tissues (n=9) stained for p19 (A) or p40 protein (B) 
and OA synovial tissues (n=8) stained for p19 (D) or p40 protein (E) using 
immunohistochemistry. Double labelling of RA synovial tissues with p19 and p40 is shown in 
(G, H). Staining with isotype matched mouse antibodies served as negative control (C, F, J). 
In (A-D) p19 and p40 protein appear in brown colour. In (G,H) p19 protein appears in brown 
and p40 in green colour. Nuclei were stained with hematoxylin.  
 
Figure 3: Cells coexpressing p40 and CD83 are found in RA synovial tissue 
Representative sections of RA synovial tissues (n=3) double labeled for p40 protein and 
CD83 by immunohistochemical analysis (A,). Staining with isotype matched mouse 
antibodies served as negative control (C). p40 appears in brown, CD83 in green colour. 
Nuclei were stained with hematoxylin.  
 
Figure 4: Low levels of soluble IL-23 in synovial fluids and sera derived from patients 
with RA 
Concentrations of heterodimeric IL-23 in RA synovial fluids (n=37), OA synovial fluids 
(n=21), RA sera (n=33) and OA sera (n=29), determined by ELISA. Each dot represents the 
average amount of soluble IL-23 from duplicates of the same individual. The detection limit 
of the ELISA (16 pg/ml IL-23) is indicated. 
 
Figure 5: Differential induction of p19 and p40 by TLR ligands 
RASF cultures (n=5), monocyte cultures (n=3) and MDDC cultures (n=3) were stimulated for 
24h with the indicated TLR ligands. Conventional PCR (A) or Real-time PCR (B) was 
performed in order to analyze p19 and p40 mRNA expression. (A) One representative 
experiment out of five is demonstrated. (B) The mean ± SEM p19 or p40 mRNA upregulation 
relative to untreated cultures is shown. 
(C) Western blot analysis of p19 expression in two individual RASF cultures, 24h following 
stimulation with the indicated TLR ligands. a-tubulin served as a loading control.  
 
Figure 6: Monocytes but not RASF secrete bioactive IL-23 after TLR activation 
CD8+ cells were preactivated with anti-CD3 and anti-CD28 antibodies and stimulated with 
rhIL-23 (A), supernatants of TLR2 ,3 and 4 activated monocytes (B) or supernatants of TLR 
2, 3 and 4 activated RASF (C). IL-23 dependent induction of IL-17 protein by CD8+  cells 
was determined by ELISA. Mean values +/- SEM are shown for 3 cultures each. 
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